Search

Ipsen SA.

Închisă

SectorFinanțe

163.6 -1.27

Rezumat

Modificarea prețului

24h

Curent

Minim

162.8

Maxim

166.4

Indicatori cheie

By Trading Economics

Venit

294M

403M

Vânzări

334M

2.2B

P/E

Medie Sector

26.133

22.368

Randament dividend

1.03

Marjă de profit

18.405

Angajați

5,535

EBITDA

556M

1B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+8.43% upside

Dividende

By Acuity

Randament dividend

Medie Sector

1.03%

4.40%

Statistici piață

By TradingEconomics

Capitalizare de piață

224M

13B

Deschiderea anterioară

164.87

Închiderea anterioară

163.6

Sentimentul știrilor

By Acuity

23%

77%

43 / 437 Clasament în Finance

Ipsen SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 aug. 2026, 23:56 UTC

News

Wayfair shares rise in after-market hours after Rosenblatt analyst Scott Devitt initiated coverage with a Buy rating and a price target of $125.00.

19 aug. 2026, 23:56 UTC

News
Social Media

Cogent Communications is facing a class action lawsuit over alleged false statements, contributing to a decline in shares during after-market hours.

19 aug. 2026, 23:52 UTC

News
Correlated Moves

Cohen & Steers Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines. The fund declared a monthly dividend of $0.126 per share.

19 aug. 2026, 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

19 aug. 2026, 23:51 UTC

News
Social Media

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

19 aug. 2026, 23:41 UTC

News

Target Corp shares are lower in after-market hours despite stronger-than-expected second-quarter earnings of $4.11 per share and a raised full-year forecast.

19 aug. 2026, 23:36 UTC

News
Social Media

Rosenblatt analyst Scott Devitt initiated coverage on Amazon.com with a Buy rating. Shares advanced in after-market trading following this positive assessment.

19 aug. 2026, 23:31 UTC

News

Wendy's Co shares are lower in after-market hours following a management reset and reports of Trian Fund Management exploring a potential buyout.

19 aug. 2026, 23:26 UTC

News

Constellation Brands announced a $100 million investment over five years to support farmers in Idaho, Montana, and North Dakota. Shares were roughly flat in after-market trading.

19 aug. 2026, 23:22 UTC

News
Social Media
Correlated Moves

Coinbase Global Inc shares are higher in after-market trading amid bullish social media sentiment and the announcement of direct USDC trading in Brazil.

19 aug. 2026, 23:21 UTC

Social Media
Correlated Moves
News

Marvell Technology shares rise in after-hours trading following a significant deal with Google, which includes a warrant for 58.97 million shares at $206.58 each.

19 aug. 2026, 23:21 UTC

Correlated Moves
News

Microstrategy Inc. shares rose in after-market trading, driven by increased bullish options activity and positive remarks on its Bitcoin strategy from executives.

19 aug. 2026, 23:21 UTC

News

Kratos Defense shares are rising in after-market trading as the U.S. Air Force evaluates alternatives to existing aerial targets, including the BQM-167A.

19 aug. 2026, 23:21 UTC

Event
Social Media
News

BILL Holdings reported strong Q4 results, with adjusted net income of $94 million. Shares are higher in after-hours trading following the earnings report.

19 aug. 2026, 23:16 UTC

News

Accuray Inc shares fell in after-market hours following a net loss of $1.94 million and revenue of $100.92 million, missing expectations.

19 aug. 2026, 23:16 UTC

News
Social Media

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

19 aug. 2026, 23:16 UTC

News
Social Media

Netflix Inc. is trading higher in after-market hours amid reports of competitive strategies in the streaming industry, including YouTube's incentives for exclusive content.

19 aug. 2026, 23:11 UTC

News

Carlyle Group invests in Castelion's $1 billion funding round, boosting defense sector engagement. Shares are higher in after-market trading following the announcement.

19 aug. 2026, 23:11 UTC

News

Northrop Grumman declared a quarterly dividend of $2.47 per share, contributing to shares trading higher in after-market hours.

19 aug. 2026, 23:11 UTC

Correlated Moves
News

The Australian Dollar is gaining against the Hong Kong Dollar amid rising global bond yields and inflation concerns linked to geopolitical tensions.

19 aug. 2026, 23:06 UTC

News

Replimune Group shares declined in after-market hours following the grant of equity awards to Chief Commercial Officer Michelle DiNapoli, raising potential dilution concerns.

19 aug. 2026, 23:06 UTC

News

Ionis Pharmaceuticals is advancing RG-6299 into a pivotal Phase III trial for IgA nephropathy in collaboration with Roche and Chugai. Shares are higher in after-market trading.

19 aug. 2026, 23:06 UTC

Social Media
News

Hims & Hers Health Inc. shares are lower in after-market trading following a lawsuit from the FTC alleging deceptive practices regarding user privacy and billing.

19 aug. 2026, 23:06 UTC

News

Chewy Inc shares are lower in after-market trading as cautious sentiment grows ahead of the September earnings call and a Neutral rating from Rosenblatt.

19 aug. 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and Fed concerns contribute to a decline in the iShares 20+ Year Treasury Bond ETF in after-market trading. The iShares TIPS Bond ETF also moves lower.

19 aug. 2026, 23:06 UTC

Social Media
News

SPDR Gold Shares trade higher after-market, boosted by social media discussions on its return above the 200-day moving average amid geopolitical tensions and inflation concerns.

19 aug. 2026, 23:06 UTC

News
Correlated Moves

Geopolitical tensions and inflation concerns support iShares Silver Trust's gains during after-market hours, maintaining a position above its 20-day moving average.

19 aug. 2026, 23:06 UTC

Correlated Moves
News

Northern Oil and Gas announced a $500 million senior notes offering, contributing to a decline in shares during after-market trading. EOG also fell amid sector dynamics.

19 aug. 2026, 23:06 UTC

News
Correlated Moves

Twist Bioscience Corp shares are lower in after-market hours following a critical short report from Scorpion Capital questioning the company's AI-driven protein design strategy.

19 aug. 2026, 23:02 UTC

News

Encore Capital Group appoints Robert Beck to its board, effective immediately. The move has contributed to shares rising in after-market trading.

Comparație

Modificare preț

Ipsen SA. Așteptări

Obiectiv de preț

By TipRanks

8.43% sus

Prognoză pe 12 luni

Medie 177.5 EUR  8.43%

Maxim 235 EUR

Minim 135 EUR

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIpsen SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

3

Păstrare

1

Vânzare

Sentiment

By Acuity

43 / 437 Clasament în Finanțe

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat